Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 20 nov 2013 - 07:30

Statutaire naam Galapagos NV

Titel Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim

Bericht Mechelen, Belgium, 20 November 2013 - Galapagos (Euronext: GLPG) announced today that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, BioFocus will apply its extensive drug discovery services to an undisclosed target within Boehringer Ingelheim's drug discovery portfolio. David Smith, CEO Services commented, "We are delighted to have secured this contract with Boehringer Ingelheim, one of the world's leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus. It is testament to the strength and depth of BioFocus' drug discovery capabilities and expertise in this particular gene family."

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201311200000000004_Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim.pdf (opens in a new window)

201311200000000004_Galapagos kondigt drug discovery samenwerking aan met Boehringer Ingelheim.pdf (opens in a new window)

Datum laatste update: 21 maart 2025